SAN DIEGO, March 15 /PRNewswire/ -- Aviva Systems Biology (ASB) (http://www.avivasysbio.com/) announced the launch of the ChIP-GLAS (Chromatin Immunoprecipitation-Guided Ligation And Selection) system, the core of its Gene Regulation Elements Mapping and Analysis (GREMA) Technology. In GREMA(TM), DNA bound to transcription factors is captured, copied, amplified, and hybridized with a microarray. The first stage launch will include both 10K and 20K ChIP-GLAS micorarrays, which cover 10,000 and 20,000 human promoter regions, and will also include supporting kits providing a complete solution for GREMA(TM).
A unique feature of GREMA(TM) is the GLAS step. In this step the DNA is annealed to oligonucleotides corresponding to promoters on the microarray. This step increases both the sensitivity and the specificity of GREMA(TM) compared to similar techniques. GREMA(TM) technology was developed in the laboratory of Dr. Xiangdong Fu, a Professor at UC San Diego and is licensed exclusively by ASB. This technology was also selected for inclusion to the NIH ENCODE (ENCyclopedia of DNA Elements) development project which aims to develop innovative technologies for the identification of functional elements within the human genome.
Using ASB's core bioinformatics capabilities, approximately 32,000 potential promoter regions have been identified in the human genome; 20,000 of these annotated promoters have been incorporated into this first wave of products. Meanwhile, more than 1,400 human transcription factor (TF) specific antibodies have also been manufactured by ASB which are scheduled to be released throughout 2005. Dr. Lingxun Duan, Executive VP of ASB states, "We are very excited to provide this unique set of products for GREMA(TM) as a complete package for the field of gene transcription study. Our additional efforts to screen each anti-TF antibody for the ChIP application on a genomic scale will provide valuable tools for our understanding of gene transcription networking." GREMA(TM) technology has many important applications which may go beyond of understanding of transcription factor/DNA interactions. It could potentially also be used for study of RNA/ protein interactions gene splicing, RNA editing, DNA damage repair, gene deletion and duplication, and many others.
Based in San Diego, California, Aviva Systems Biology is dedicated to the development of unique technology platforms for gene transcription regulatory study. Learn more about ASB products and technologies at http://www.transcriptionfactor.com/.
Contact Information: Dr. Cynthia Lane 858-552-6979 x106 clane@avivasysbio.com
Aviva Systems BiologyCONTACT: Dr. Cynthia Lane of Aviva Systems Biology, +1-858-552-6979ext. 106, clane@avivasysbio.com
Web site: http://www.transcriptionfactor.com/
Web site: http://www.avivasysbio.com/